An acidic polysaccharide Chlon A, from Chlorella
Pyrenoidosa
Kanki Komiyama, Yumiko Hirokawa, Takashi Morota
and lwao Umezawa
The Kitasato Institute
An acidic polysaccharide, chlon A, from Chlorella
PYrenOid0sa
2. Antitumor activity and immunological
response
Chlon A, an acidic polysaccharide purified from the hot water extract of Chlorella
pyrenoidosa, possessed antitumor activity against transplantable murine tumors in
vivo. In allogeneic systems, Chlon A showed remarkable life prolongation effects in mice
bearing Sarcoma 180 with a broad optimal dose range. Chlon A was also active in syngeneic
systems such as IMC carcinoma, Meth A fibrosarcoma, B16 melanoma and Lewis lung carcinoma
growing in the intraperitoneal cavity. When Meth A cells were admixed with Chlon A and
inoculated sc, remarkable growth inhibition of tumor cells was observed. Chlon A enhanced
cytotocicity of mice macrophages for EL-4 tumor cells in vivo, lymphoproliferative effects
in vitro, and carbon clearance activity (reticuloendothelial system) in vivo. The
electrophoretic pattern showed that LA (ceruloplasmin) and/or LB (hemopexin)like
components rapidly appeared in serum proteins of mice receiving Chlon A. These findings
indicate that Chlon A is a potent modifier of some biological responses.
Table 2. Antitumor activity of Chlon A on
Sarcoma 180 and Meth-A fibrosarcoma.
Mice were given with Chlon A from days 1 to 5 and 7 to 1 1.
a) Numbers in parentheses indicate the number of cured mice/seven
treated mice. Cured mice were excluded from the calculation of I LS (%).
b) Zymosan was purchased from SIGMA Chemical Company (ST. Louis, USA).
Table 3. Antitumor activity of Chlon A on IMC carcinoma,
P388 leukemia Lewis lung carcinoma and B-16 melanoma.
Mice were given with Chlon A from days 1 to 5 and 7 to 1 1.
Table 4. In vivo growth of Meth A cells mixed with Chlon
A.
Meth A cells suspended in minimum essential medium were admixed with Chlon A in
vitro, and incubated for 30 minutes at 37oC. After incubation, tumor cells were
inoculated subcutaneously into BALB/c mice, and tumor growth was measured periodically by
calipers.
Table 5. Lymphoproliferative effect of Chlon A.
Spleen cells from normal mice were mixed with Chlon A, incubated for 72 hours at 37oC,
and the uptake of 3 H-TdR into spleen cells was measured.
Table 6. Carbon clearance in mice treated with Chlon A.
Normal ddY mice received Chlon A (once a day for 2 days, iv). On day 3, mice were
injected iv with India ink (Pelican Fount India) and blood was withdrawn periodically from
the retro-orbital plexus. Phagocytic activity was measured by the method of Halpern3).
Fig. 1. Antitumor activity of Chlon A on Sarcoma 180 solid
tumors.
Mice were given Chlon A iv on days 1, 3, 5, 7 and 9.
Fig. 2. Effect of Chlon A on the cytolytic activity of
peritoneal exudate cells.
Adherent peritoneal exudate cells (PEC) of ddY mice were collected on day 1 or 4 after
injection of Chlon A and were mixed with EL-4 cells previously labeled with 3
H-uridine. After incubation for 16 hours, the radioactivity of E L-4 cells was measured.
(1-T/C) x 100 (%). The mean radio-activity of the control group was 5,931 cpm.
Fig. 3. Effect of Chlon A on the cytostatic
activity of peritoneal exdate cells.
Adhearent peritoneal exudate cells (PEC) of ddY mice were collected on day 1 or 4
after injection of Chlon A. Then 3 H-TdR (1 ug/ml) was added to the cell
mixture, and incubation was further continued for 5 hours. The uptake of 3 H-TdR
into EL-4 cells was measured. (1 -T/C) x 1 00 (%). The mean radioactivity of the control
group was 6,332 cpm.
Fig. 4. Effect of Chlon A on the
electrophoretic pattern of mouse serum.
Chlon A was injected iv into normal ddY mice on day 0, and sera were obtained on days
3, 5, 7, and 9. Sera were subjected to polyacrylamide gel electrophoresis on gradient gel.
After electrophoresis, the gel was stained with 15 Amidoblack 10B solution.
TABLE 1
Tumor used in this Experiment |
| Tumor |
Animal |
Inoculum size |
| cells/mouse |
Inoculum site |
| Sarcoma 180 |
ICR 6w female |
1 X 105 |
ip or sc |
| IMC carcinoma |
CDF1 6w female |
1 X 105 |
ip |
| Meth A fibrosarcoma |
BALB/c 6w female |
1 X 106 |
ip or sc |
| B16 melanoma |
C57 BL 6w female |
1 X 106 |
ip |
| Lewis lung carcinoma |
C57 BL 6w female |
1 X 106 |
ip |
| P388 leukemia |
CDF1 6w female |
1 X 105 |
ip |
TABLE 2
Antitumor activity of Chlon-A on
Sarcoma 180 and
Meth-A fibrosarcoma (ip-ip) |
Sample |
Total dose (mg/kg) |
Sarcoma 180 |
Meth -A fibrosarcoma |
MSD |
(range) |
ILS |
(%) |
MSD |
(range) |
ILS |
(%) |
Saline |
--- |
13.9 |
(11-18) |
--- |
0 |
13.3 |
(13-14) |
--- |
0 |
Zymosanb) |
20
x 10 |
20.3 |
(13-34) |
46
|
(1) |
15.4** |
(15-16) |
15.8 |
(0) |
5 x 10 |
17.1* |
(15-22) |
23 |
(0) |
15.6** |
(14-17) |
17.3 |
(0) |
Chlon-A |
100
x 10 |
22.9** |
(10-43) |
64.7 |
(0) |
17.8** |
(16-19) |
33.8 |
(1) |
25 x 10 |
31** |
(15-41) |
123 |
(2) |
20** |
(17-25) |
50.4 |
(0) |
6.25 x 10 |
49.5** |
(39-54) |
256 |
(1) |
20** |
(15-27) |
50.4 |
(0) |
1.56 x 10 |
26.3** |
(12-57) |
89 |
(1) |
15.6 |
(12-17) |
17.3 |
(0) |
*p < 0.05 **p < 0.01 |
Numbers in parenthesis indicate number of cured mice/7 treated
mice.
Cured mice were excluded from the calculation of I LS (%).
Zymosan was purchased from SIGMA chemical company (ST. Louis, USA).
TABLE 3
Antitumor activity of Chlon-A on IMC carcinoma, P388 leukemia,
Lewis lung carcinoma and B-16 melanoma (ip-ip) |
| |
IMC carcinoma |
P388 leukemia |
Lewis lung carcinoma |
B-16 melanoma |
| Sample |
Total dose
(mg/kg) |
MSD
(range) |
I LS
(%) |
MSD
(range) |
ILS
(%) |
MSD
(range) |
I LS
(%) |
MSD
(range) |
I LS
(%) |
| Saline |
--- |
14.8
(14-16) |
--- |
12 |
--- |
18.2
(10-22) |
--- |
16.2
(14-18) |
--- |
| Chlon-A |
100 x 10 |
24.4**
(20-23) |
44.6 |
1.1 |
-8.3 |
25.8*
(22-30) |
41.8 |
24**
(20-31) |
48.1 |
| 2 5 x
1 0 |
21.6**
(20-25) |
45.9 |
12.2
(11-13) |
1.7 |
21.8
(15-27) |
19.8 |
21.4
**
(18-24) |
32.1 |
| 6.25 x
10 |
22.4**
(20-23) |
51.4 |
1.1 |
-8.3 |
23.8
(21-27) |
30.5 |
23**
(19-26) |
42 |
| 1.56 x
10 |
20.6**
(20-23) |
39.2 |
11.2
(11-12) |
-6.7 |
20.6
(17-23) |
13.2 |
23.6* (19-31) |
45.7 |
*p < 0.05 **p < 0.01 |
TABLE 4
In vivo growth of Meth-A cells mixed with Chlon A |
Dose
(mg/kg) |
|
Tumor size (mm2) |
Days |
7 |
14 |
21 |
27 |
Saline |
|
68.4 |
234.4 |
510 |
686.6 |
200 |
|
+** |
24.6**
(90) |
84.3*
(83) |
175.6**
(74.4) |
40 |
|
5.7**
(91.7) |
47.6**
(79.7) |
159**
(69) |
331**
(51.8) |
8 |
|
14.57**
(78.7) |
75.3**
(67.9) |
208.4*
(59) |
445.1**
(35.2) |
1.6 |
|
32.7**
(62.2) |
124.1**
(47.1) |
382.7
(25) |
631.8
(8) |
*p
< 0.05 **p < 0.01 |
Numbers in parenthesis indicate percent inhibition of tumor
growth.
TABLE 5
Lymphoproliferative effect of Chlon-A |
Sample |
Dose
(ug/ml) |
H-TdR count
(cpm) |
Stimulation
index |
Saline |
|
902.3 |
1 |
Con A |
5
1 |
14988.2
83046.5 |
16.6
92 |
LPS |
50
12.5 |
18097.2
22856.9 |
20
25.3 |
Chlon-A |
1000
250
62.5
15.6
3.9 |
22208.5
17534.4
7992.7
5761.5
3456.7 |
24.6
19.4
8.9
6.4
3.4 |
TABLE 6$ Carbon clearance in mice treated with Chlon-A |
Total
dose
(mg/kg) |
Phagocytic
index (k) |
spleen
weight
(mg) |
Liver
weight
(g) |
--- |
0.0079 |
113 ±
21 |
1.495
± 0.09 |
100 |
0.0086
± 0.002 |
197 ±
27 |
1.478
± 0.07 |
25 |
0.0105
± 0.001 |
205 ±
22 |
1.420
± 0.08 |
6.25 |
0.0113*
± 0.001 |
185 ±
24 |
1.580
± 0.1 |
*p < 0.l |
Fig. 1 Effect of Chlon A on Sarcoma 180 Solid Tumor

Days after tumor inoculation

Fig. 2 Effect of Chlon A on the cytolytic activity of
peritoneal exdate cells
Fig. 3 Effect of Chlon A on the cytostatic activity of peritoneal
exdate cells
Fig. 4 Change of serum fraction by Chlon A

Gel: 4-30% gradient (polyacryl amide)
Buffer: 0.025M Tris-0.19M glicine 10 mA, 17 hrs. |